Effect of allogeneic HCT from unrelated donors in AML patients with intermediate- or poor-risk cytogenetics: a retrospective study from the Japanese Society for HCT

Satoshi Yamasaki, Jinichi Mori, Junya Kanda, Nobuhiko Imahashi, Naoyuki Uchida, Noriko Doki, Masatsugu Tanaka, Yuta Katayama, Tetsuya Eto, Yukiyasu Ozawa, Satoru Takada, Makoto Onizuka, Masayuki Hino, Yoshinobu Kanda, Takahiro Fukuda, Yoshiko Atsuta, Masamitsu Yanada

Research output: Contribution to journalArticlepeer-review

Abstract

This study aimed to analyze the factors associated with outcomes of bone marrow transplantation (UR-BMT) or cord blood stem cell transplantation from unrelated donors (UR-CBT). We assessed the time from diagnosis to transplantation among acute myeloid leukemia (AML) patients with intermediate- or poor-risk cytogenetics to identify the potential clinical efficacy of transplantation. We retrospectively analyzed 5331 patients who received UR-BMT or UR-CBT between 2008 and 2017. Patients were divided into four groups according to time from diagnosis to transplantation: (1) UR-BMT and > 5 months (n = 2353), (2) UR-BMT and ≤ 5 months (n = 379), (3) UR-CBT and > 5 months (n = 1494), and (4) UR-CBT and ≤ 5 months (n = 1106). There was no difference in overall survival (OS) for transplantation at ≤5 months and > 5 months in patients with first complete remission for both UR-BMT and UR-CBT, but OS in patients with primary induction failure (PIF) and transplantation at ≤ 5 months was significantly higher in the UR-CBT group compared with that at >5 months (P < 0.001). Multivariate Cox regression analysis also showed that transplantation at >5 months in patients with PIF was an independent predictor of poorer OS. Therefore, UR-CBT at ≤ 5 months after diagnosis is an alternative option for AML patients with PIF.

Original languageEnglish
Pages (from-to)2927-2937
Number of pages11
JournalAnnals of Hematology
Volume99
Issue number12
DOIs
Publication statusPublished - Dec 2020
Externally publishedYes

All Science Journal Classification (ASJC) codes

  • Hematology

Fingerprint Dive into the research topics of 'Effect of allogeneic HCT from unrelated donors in AML patients with intermediate- or poor-risk cytogenetics: a retrospective study from the Japanese Society for HCT'. Together they form a unique fingerprint.

Cite this